Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesús García-Donás, Emilio Esteban, Luis Javier Leandro-Garcia et al. · The Lancet Oncology · 2011
Cited by 225 works. doi:10.1016/s1470-2045(11)70266-2
Authors
- Jesús García-Donás
- Emilio Esteban
- Luis Javier Leandro-Garcia
- Daniel Castellano
- Aranzazu González del Alba
- Miguel Ángel Climent
- José Ángel Arranz
- Enrique Gallardo
- Javier Puente
- Joaquim Bellmunt B
- Begoña Mellado
- Esther Martínez
- Albert Font Pous
- Mercedes Robledo
- Cristina Rodríguez‐Antona
References
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
- Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
- Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
- Molecular basis for sunitinib efficacy and future clinical development
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib